Xtandi 80 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FJNV6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,021
Award facts
- Contract value 100% obligated
- $17,021.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $17,021.36 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count packages). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order is scheduled for completion by November 26, 2025, with performance to take place at the contractor's Park Ridge facility.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to provide the Department of Defense with a reliable pharmaceutical supply chain, and DMS Pharmaceutical Group serves as one of multiple regional prime vendor contractors. The IDC authorizes the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription medications, biologics, and medical consumables to support military healthcare facilities worldwide. No subcontractors are identified in this award documentation.
Quick answers
Who was awarded contract SPE2DR26FJNV6?
SPE2DR26FJNV6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 25, 2025.
How much is contract SPE2DR26FJNV6 worth?
The government has obligated $17,021 on SPE2DR26FJNV6.
Is contract SPE2DR26FJNV6 an order under another contract?
Yes. SPE2DR26FJNV6 is a delivery order under SPE2DR25D9226, an indefinite delivery contract.
Was contract SPE2DR26FJNV6 competed?
The extent of competition for SPE2DR26FJNV6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award